创伤性脑损伤
生产过剩
活性氧
炎症
氧化应激
医学
冲程(发动机)
疾病
生物信息学
免疫学
酶
内科学
生物
病理
细胞生物学
生物化学
精神科
机械工程
工程类
作者
Yunfan Yang,Zi-Xiang Li,Xiaochong Fan,Chao Jiang,Junmin Wang,Yousef Rastegar-Kashkooli,Tom J. Wang,Junyang Wang,Menglu Wang,Nannan Cheng,Xiqian Yuan,Xuemei Chen,Bing Jiang,Jian Wang
出处
期刊:ACS Nano
[American Chemical Society]
日期:2024-06-19
卷期号:18 (26): 16450-16467
被引量:2
标识
DOI:10.1021/acsnano.4c03425
摘要
Nanozymes, which can selectively scavenge reactive oxygen species (ROS), have recently emerged as promising candidates for treating ischemic stroke and traumatic brain injury (TBI) in preclinical models. ROS overproduction during the early phase of these diseases leads to oxidative brain damage, which has been a major cause of mortality worldwide. However, the clinical application of ROS-scavenging enzymes is limited by their short in vivo half-life and inability to cross the blood-brain barrier. Nanozymes, which mimic the catalytic function of natural enzymes, have several advantages, including cost-effectiveness, high stability, and easy storage. These advantages render them superior to natural enzymes for disease diagnosis and therapeutic interventions. This review highlights recent advancements in nanozyme applications for ischemic stroke and TBI, emphasizing their potential to mitigate the detrimental effect of ROS overproduction, oxidative brain damage, inflammation, and blood-brain barrier compromise. Therefore, nanozymes represent a promising treatment modality for ROS overproduction conditions in future medical practices.
科研通智能强力驱动
Strongly Powered by AbleSci AI